Adalimumab safety in global clinical tri
β
Jean-FrΓ©dΓ©ric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson;
π
Article
π
2009
π
John Wiley and Sons
π
English
β 145 KB
π 2 views
Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr